Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IDL Diagnostics ABOSTO:IDLDX +3.69%55 Days Payable is 78.88 as of Mar. 2026, which is 10% above its 10-year median of 71.67. GuruFocus rates OSTO:IDLDX with a GF Score™ of 55/100 and a GF Value™ of kr0.54 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 190 Medical Diagnostics & Research companies, IDL Diagnostics AB ranks worse than 55.79% on this metric.
The historical rank and industry rank for IDL Diagnostics AB's Days Payable or its related term are showing as below:
OSTO:IDLDX'
s Days Payable Range Over the Past 10 Years
Min: 37.73 Med: 71.67 Max: 46407.14
Current: 57.18
During the past 13 years, IDL Diagnostics AB's highest Days Payable was 46407.14. The lowest was 37.73. And the median was 71.67.
OSTO:IDLDX's Days Payable is ranked worse than 55.79% of 190
companies
in the Medical Diagnostics & Research industry
Industry Median: 64.64
vs OSTO:IDLDX: 57.18
IDL Diagnostics AB's Days Payable
increased
from Mar. 2025 (54.53) to Mar. 2026 (78.88).
It may suggest that IDL Diagnostics ABdelayed paying its suppliers.
IDL Diagnostics AB Days Payable Related Terms
IDL Diagnostics AB Days Payable Historical Data
* Premium members only.
The historical data trend for IDL Diagnostics AB's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:IDLDX vs TMO, DHR, IDXX: Days Payable Comparison
For the Diagnostics & Research subindustry, IDL Diagnostics AB's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IDL Diagnostics AB Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, IDL Diagnostics AB's Days Payable distribution charts can be found below:
* The bar in red indicates where IDL Diagnostics AB's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
IDL Diagnostics AB's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IDL Diagnostics AB (OSTO:IDLDX) has a Days Payable of 78.88 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on IDL Diagnostics AB and its competitors. This is 10% above median its historical median of 71.67. Over the past decade, IDL Diagnostics AB's Days Payable has ranged from 37.73 to 46,407.14. According to the industry distribution chart, IDL Diagnostics AB ranks #106 out of 190 companies in the Medical Diagnostics & Research industry, placing it in the top 55.8%.
Is IDL Diagnostics AB's Days Payable too high?
IDL Diagnostics AB's current Days Payable of 78.88 is 10% above median its 10-year median of 71.67. Over the past 10 years, this metric has ranged from a low of 37.73 to a high of 46,407.14. The Medical Diagnostics & Research industry median Days Payable is 64.64. IDL Diagnostics AB's value of 78.88 is 22% above this industry median. Based on the distribution chart, IDL Diagnostics AB ranks #106 out of 190 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, IDL Diagnostics AB has a GF Score™ of 55/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does IDL Diagnostics AB's Days Payable compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, IDL Diagnostics AB ranks #106 out of 190 companies for Days Payable. This places IDL Diagnostics AB in the lower half of its industry. The industry median Days Payable is 64.64. IDL Diagnostics AB's value of 78.88 is 22% above this benchmark. Historically, IDL Diagnostics AB's own Days Payable has ranged from 37.73 to 46,407.14 over the past decade. While the company's 10-year median is 71.67 vs. the industry median of 64.64, IDL Diagnostics AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 64.64, based on 190 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IDL Diagnostics AB's current Days Payable of 78.88 is 22% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on IDL Diagnostics AB and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 64.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IDL Diagnostics AB's current Days Payable is 78.88, which is 10% above median its own 10-year median of 71.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDL Diagnostics AB stock overvalued right now?
Based on GuruFocus' analysis, IDL Diagnostics AB (OSTO:IDLDX) is currently considered Modestly Undervalued. The stock's GF Value™ is kr0.54, compared to a current price of kr0.42 — trading 21.9% below its estimated fair value. The current Days Payable is 78.88, which is 10% above median its 10-year median of 71.67 and 22% above the Medical Diagnostics & Research industry median of 64.64. IDL Diagnostics AB's overall GF Score™ is 55/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For IDL Diagnostics AB (OSTO:IDLDX), the current Days Payable is 78.88 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IDL Diagnostics AB (OSTO:IDLDX) Overvalued in 2026?
Based on GuruFocus' analysis, IDL Diagnostics AB stock appears to be undervalued.
The current stock price of kr0.42 is trading 21.9% below its estimated GF Value™ of kr0.54.
GuruFocus considers IDL Diagnostics AB to be Modestly Undervalued.
Key valuation signals for OSTO:IDLDX:
Days Payable: 78.88 (10% above median its 10-year median of 71.67)
GF Value™: kr0.54 vs. price of kr0.42 (21.9% below fair value)
Industry Position: 22% above the Medical Diagnostics & Research median (#106 of 190)
No single metric tells the full story. See the OSTO:IDLDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
IDL Diagnostics AB is a Swedish company that develops and markets blood and urine sample tests. It specializes in oncology and bacteriology. The company has a broad product portfolio, is used in healthcare, and is established in various markets. In oncology, IDL Diagnostics uses various biomarkers, TK1 and cytokeratins, to support the treatment of cancers such as breast, prostate, and bladder cancers.
55GF Score
Get the complete analysis for OSTO:IDLDX
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:IDLDX has been successfully added to your 
